Skip to content
  • Home
  • About Us
  • Longevity Platform
  • Bio101
    • BIO101 in Sarcopenia
    • BIO101 in Obesity
  • Other Projects
  • Resources
    • Posters & Publications
    • Scientific Press Releases
  • Recruitment
  • Investors
    • Stock Information
    • Corporate Presentation
    • Letter to shareholders
    • Press Releases
    • General Meetings
    • AMF Regulated Information
    • SEC Filings
    • Convertible bonds
    • Contact for Investors
  • Contact
  • EN
  • Home
  • About Us
  • Longevity Platform
  • Bio101
    • BIO101 in Sarcopenia
    • BIO101 in Obesity
  • Other Projects
  • Resources
    • Posters & Publications
    • Scientific Press Releases
  • Recruitment
  • Investors
    • Stock Information
    • Corporate Presentation
    • Letter to shareholders
    • Press Releases
    • General Meetings
    • AMF Regulated Information
    • SEC Filings
    • Convertible bonds
    • Contact for Investors
  • Contact
  • EN
  • EN
  • EN

JULY 19, 2021

Press Releases, StrategyBy adminJuly 20, 2021

Judgment rendered on July 16, 2021 in the proceedings between Biophytis and Negma Group Ltd by the Execution Judge from the Paris Court of Justice

X
Addresses
Addresses

BIOPHYTIS France
Silver Innov’
54 rue Molière
94200 Ivry-Sur-Seine
FRANCE

Addresses

BIOPHYTIS USA
c/o NGIN
210 Broadway, Suite #201
Cambridge, MA 02139
USA

Addresses

BIOPHYTIS Brazil
CIETEC
Av. Prof. Lineu Prestes
2242 Cidade Universitária USP
05508-000 São Paulo
BRASIL

Contact
contact@biophytis.com
+33 144 272 300
Investors

investors@biophytis.com

© Biophytis 2025.

All Rights Reserved.

Legal information

Webdesign by Ex Calibra

Go to Top
  • Home
  • About Us
  • Longevity Platform
  • Bio101
    • BIO101 in Sarcopenia
    • BIO101 in Obesity
  • Other Projects
  • Resources
    • Posters & Publications
    • Scientific Press Releases
  • Recruitment
  • Investors
    • Stock Information
    • Corporate Presentation
    • Letter to shareholders
    • Press Releases
    • General Meetings
    • AMF Regulated Information
    • SEC Filings
    • Convertible bonds
    • Contact for Investors
  • Contact